Donor-specific antibodies adversely affect kidney allograft outcomes. - Wikidata - wikimedia - TriplyDB

Donor-specific antibodies adversely affect kidney allograft outcomes.

Donor-specific antibodies adversely affect kidney allograft outcomes.

http://www.wikidata.org/entity/Q36426146

about

New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity Factors influencing long-term outcome after kidney transplantation Memory B cells in transplantation Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients Early acute antibody-mediated rejection of a negative flow crossmatch 3rd kidney transplant with exclusive disparity at HLA-DP.Diagnosis and management of antibody-mediated rejection: current status and novel approaches.Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.HLA sensitisation: can it be prevented?Antibody-Dependent NK Cell Activation Is Associated with Late Kidney Allograft Dysfunction and the Complement-Independent Alloreactive Potential of Donor-Specific Antibodies A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance.B cells in transplantation.Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study.From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications.Antibody-Mediated Rejection: A Review.Nephrectomy for the failed renal allograft in children: predictors and outcomes.The specificity of acute and chronic microvascular alterations in renal allografts.Pretransplant identification of acute rejection risk following kidney transplantation.Immunosuppression and allograft rejection following lung transplantation: evidence to date.The increasing clinical importance of alloantibodies in kidney transplantation.Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection.Simultaneous pancreas and kidney transplantation: current trends and future directions.B-cell biomarkers in transplantation--from genes to therapy.Humoral immunity in renal transplantation: epitopes, Cw and DP, and complement-activating capability--an update.Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival.Kidney retransplantation in children following rejection and recurrent disease.Biomarkers in pancreas transplant.Clinical and immunological relevance of antibodies in solid organ transplantation.Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.Inter-individual differences in HLA expression can impact the CDC crossmatch.Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis.The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes.Diagnosis and Treatment of Pancreas Rejection.False-positive reactions against HLA class II molecules detected in Luminex single-antigen bead assays.Development of immune response to tissue-restricted self-antigens in simultaneous kidney-pancreas transplant recipients with acute rejection.Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies.Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome.Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients.

P2860

Q26823090-E90FCF2A-B258-42CD-BC69-89091CB8EA8E Q26825480-13A2C44B-8E5F-4C9C-8511-A3F74CDC40FE Q26829296-195F4658-4392-448F-ADDF-3F90454E0FE7 Q33930084-55EBE771-D3D3-4570-81FE-F9AF06ED88B2 Q33993707-9F0A00B6-81E4-4E86-B920-70FDD4F6B3D3 Q34841849-DEBC9FDC-4D25-483F-8D43-EE1484D15B9B Q35027253-7161F9D2-F9D8-4CAD-8C9C-18031095AF5A Q35097898-677B3622-2337-4468-B0F5-3B575CBC67C1 Q36113914-61AEBFFF-23E9-4943-8739-7AE5BE1CF15D Q36194995-336BDE51-453A-46F0-BC55-B69DBD4CD5CA Q36663036-52598345-FBEB-4D5F-A024-4490933CAFAE Q37029874-D3EC4F3E-7C54-41C8-8291-52996AF7ACE0 Q37097768-3D8D9450-E154-42CB-94C6-0C5DEBDA3D25 Q37590820-FED4928B-0D5E-42BB-B925-E677A198DF2C Q37642331-D01D2043-4EB7-4EF1-91D7-AAC04E2880F8 Q37698860-66E6E127-9256-43CB-9301-8D578E48117E Q38100687-09813559-5B1F-44CF-B41B-024999DC9C11 Q38151921-F2EE1F68-BB6C-4EBA-A1D6-069C7B928F63 Q38151922-2812F2C1-71F2-4296-9355-F8F2294ADC02 Q38154197-E85DBD5F-1212-4F58-8624-03BEEE522CAA Q38258153-12A5BA64-C8F0-419D-AC7A-F4EFE64CC128 Q38282840-F9FB5FE8-9898-47AF-9E88-8CE2A2CCF19C Q38309889-11F7D695-A818-43E2-915A-A7AE1052321F Q38334458-1D589E3A-D986-45CE-B1FC-5EFFBDB03535 Q38341785-1A24FC15-72B4-47C6-975B-30C4A2C9491D Q38429887-605B8254-8A6E-427B-B87C-90C39B524567 Q38798905-90FA8933-ADDC-4CEF-BED5-822451466140 Q38848032-5B83A087-E4B8-481B-8A58-290FA41F03C9 Q39015291-811333AB-99D4-4448-BAD8-1EDB9A9578CC Q39808031-FD8A3059-D37F-445D-ACA5-7AF07ED89C15 Q41197451-DC236A97-65BF-4B62-8C78-0DB8FBAD6637 Q41495990-0C541BE8-EA1D-4179-80FA-B6D518A671C2 Q41946081-B866C99D-820F-4124-9A31-77E4CBD3BB16 Q42233729-E47E50C8-E1EA-45AE-A9B1-76EEA6053E2C Q42554733-BCCFBBDE-FBC7-4392-A115-433D77A3E21A Q42854881-5F40EB62-CBB6-49F7-AA83-EAB9544FE64A Q45982490-0FDBF022-F0F2-40E9-849E-90ABCB4D0BB4 Q46456694-70D2FFC8-31AC-49DB-AB45-1B54F66755E4 Q47130649-5130CFB7-62FF-4EFA-BDFB-D0C3E270DF69 Q47313617-B8E9184D-E541-4C58-97C2-7F991719DD95

P2860

Donor-specific antibodies adversely affect kidney allograft outcomes.

http://www.wikidata.org/entity/Q36426146

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Donor-specific antibodies adversely affect kidney allograft outcomes.

@ast

Donor-specific antibodies adversely affect kidney allograft outcomes.

@en

type

label

Donor-specific antibodies adversely affect kidney allograft outcomes.

@ast

Donor-specific antibodies adversely affect kidney allograft outcomes.

@en

prefLabel

Donor-specific antibodies adversely affect kidney allograft outcomes.

@ast

Donor-specific antibodies adversely affect kidney allograft outcomes.

@en

P1433

Q36426146-1465315A-B88D-4973-9A27-47215578DFD7

P1476

Q36426146-9EC18710-CF15-4717-93EA-84E95107EB57

P2093

Q36426146-00B3B2BA-F7FD-4A20-8131-01BD9337ED13

Q36426146-33DD895B-EC17-4D67-99C7-AF2A56FBC8DC

Q36426146-3E2A84A7-E01E-4136-B084-4E8ECF90C06E

Q36426146-69FB16E5-50E4-4A3B-A0A2-C04A7A572E54

Q36426146-77EABF54-6898-442A-B035-C1D02524724A

Q36426146-7DD73638-B980-4F69-BCF1-F95AF82B2F73

Q36426146-7F44DBBF-B733-48D2-979D-20A15203ED98

Q36426146-D7CEFEEE-F141-4BD5-BCF3-F6A0C13239BD

P2860

Q36426146-0BEE573A-5F82-4ED6-A697-0B1B4067E22F

Q36426146-16FBCB92-5F11-474B-889B-74317241132C

Q36426146-18035882-81B1-4D92-9A0C-27E18B879F21

Q36426146-1BFF4CB3-6FE4-4818-A736-3B5EC75780D1

Q36426146-1FD8DAF0-FB5D-4414-8DC8-6F9C44E7B6A2

Q36426146-26CE4662-6FBF-460A-A925-318C6DA10DDA

Q36426146-367EA83C-F635-4CB2-A6EF-062CC9CDE3BC

Q36426146-4AD34A43-9512-466E-923D-5FFADC76D028

Q36426146-5E1DC240-45ED-4DA6-83CD-8F01D944EA11

Q36426146-79129365-A200-4AF8-A1AF-C06EF9F6906C

P304

Q36426146-A5C8E90E-76D3-4836-9C50-EDC3C2F0F8A5

P31

Q36426146-1B244B33-337A-460E-8206-CD9291E850B1

Q36426146-3ab35d5d-aec0-409b-980b-f489d7273988

Q36426146-5ab2e538-9dd0-4934-8253-1bdb9df14290

P356

Q36426146-5058B163-E956-47CB-99F9-61F97C57B491

P433

Q36426146-495DC31E-10E2-4743-82EC-306969428D30

P478

Q36426146-09C112D3-9879-4B26-88B2-F15ED2767086

P50

Q36426146-C457E65C-DD99-4B46-A34D-FD8E293AD369

P577

Q36426146-1A2C5165-3EB0-4CC2-A982-544601D2F895

P5875

Q36426146-B36BA569-DE0E-42F5-BFE5-EB960E6E3267

P698

Q36426146-8E2A42D1-DF17-4B8B-8608-52B8A038E054

P921

Q36426146-0ADC311D-6998-4D29-8989-6CA988D3AB91

P932

Q36426146-96D5262E-B94E-4F39-8E78-34AFD00A4D2F

P356

P1433

Journal of the American Society of Nephrology

P1476

Donor-specific antibodies adversely affect kidney allograft outcomes

@en

P2093

Amudha Palanisamy

http://www.w3.org/2001/XMLSchema#string

Bekir Tanriover

http://www.w3.org/2001/XMLSchema#string

David J Cohen

http://www.w3.org/2001/XMLSchema#string

Demetra Tsapepas

http://www.w3.org/2001/XMLSchema#string

Geoffrey Dube

http://www.w3.org/2001/XMLSchema#string

Jai Radhakrishnan

http://www.w3.org/2001/XMLSchema#string

Lloyd E Ratner

http://www.w3.org/2001/XMLSchema#string

R John Crew

http://www.w3.org/2001/XMLSchema#string

P2860

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Operating characteristics of a rank correlation test for publication bias

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation

Revisiting traditional risk factors for rejection and graft loss after kidney transplantation

Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.

Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification.

Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch.

Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch.

P304

2061-2071

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2012070664

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233537785

http://www.w3.org/2001/XMLSchema#string

P698

23160511

http://www.w3.org/2001/XMLSchema#string

P921

P932

3507372

http://www.w3.org/2001/XMLSchema#string